These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10593713)

  • 21. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R; Singh I; Kaur KJ; Kaul CL
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):625-8. PubMed ID: 10669909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form.
    Agrawal S; Kaul CL; Panchagnula R
    Pharmazie; 2001 Aug; 56(8):636-9. PubMed ID: 11534341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.
    Agrawal S; Kaur KJ; Singh I; Bhade S; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Nov; 9(11):1273-80. PubMed ID: 16333937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur K; Singh I; Bade SR; Ashokraj Y
    Int J Pharm; 2006 Apr; 313(1-2):5-13. PubMed ID: 16517107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA; Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
    McIlleron H; Wash P; Burger A; Folb P; Smith P
    Int J Tuberc Lung Dis; 2002 Apr; 6(4):356-61. PubMed ID: 11936746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects.
    Milán-Segovia RC; Vigna-Pérez M; Romero-Méndez MC; Medellín-Garibay SE; Vargas-Morales JM; Magaña-Aquino M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2014 Jan; 18(1):49-54. PubMed ID: 24365552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers.
    van Crevel R; Nelwan RH; Borst F; Sahiratmadja E; Cox J; van der Meij W; de Graaff M; Alisjahbana B; de Lange WC; Burger D
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):500-3. PubMed ID: 15141745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
    Singh S; Mariappan TT; Bhutani H
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):701-2. PubMed ID: 15971403
    [No Abstract]   [Full Text] [Related]  

  • 34. Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.
    Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S362-7; discussion S381-7. PubMed ID: 10593719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed-dose combination formulations for tuberculosis treatment.
    Sbarbaro J; Blomberg B; Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S286-8. PubMed ID: 10593706
    [No Abstract]   [Full Text] [Related]  

  • 36. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):689-94. PubMed ID: 11294011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of bioavailability of two brands of rifampicin.
    Rewari S; Rath R; Gupta U
    J Assoc Physicians India; 1998 Aug; 46(8):751. PubMed ID: 11229300
    [No Abstract]   [Full Text] [Related]  

  • 40. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.
    Panchagnula R; Agrawal S
    Int J Pharm; 2004 Mar; 271(1-2):1-4. PubMed ID: 15129967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.